Reported in Shenzhen on September 11, 2025
With the aging population and advances in medical technology, the demand for medical grade silicone materials is experiencing explosive growth. In 2025, domestic enterprises will break through international certification barriers and accelerate the landing of products such as biodegradable silicone rubber vascular stents and insulin pump seals. The market for billion dollar implant materials is about to open.


Vascular stent: biodegradable material replaces metal stent
Traditional metal stents need to be permanently retained in the body, which can easily cause thrombosis and restenosis; The biodegradable silicone rubber stent can be fully absorbed within 18-24 months, reducing the risk of complications. In 2025, the polylactic acid silicone rubber composite stent developed by domestic enterprises has passed the certification of the US FDA and the EU CE. Clinical data shows that its restenosis rate is 40% lower than that of metal stents.


At present, the product has entered the medical insurance catalog, with a single unit price reduced from 30000 yuan to 12000 yuan, driving the market penetration rate from 5% to 25%. It is expected that domestic sales will exceed 500000 units by 2025, with a market size of 6 billion yuan.


Insulin pump: domestication of seals to reduce costs
Insulin pumps need to be used in close contact with the skin for a long time, with extremely high requirements for the biocompatibility and aging resistance of the seals. In 2025, liquid silicone (LSR) seals developed by domestic enterprises will pass ISO 10993 biosafety certification, extending their service life from 3 years to 5 years and reducing costs by 40% compared to imported products.


At present, its products have been supplied to multiple leading medical device companies, with an installed capacity of over 2 million units and a market share of over 30%. It is expected that the market size will reach 1.5 billion yuan by 2025, with a compound annual growth rate of 25%.